ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Zynerba Pharmaceuticals, Inc.

80 West Lancaster Avenue
Suite 300
Devon, PA 19333
United States

IndustryDrugs - Generic
Full Time Employees12

Key Executives

Mr. Armando AnidoChairman and Chief Exec. Officer901.21kN/A59
Ms. Terri B. SebreePres681.77kN/A59
Mr. James E. FickenscherChief Financial Officer and VP of Corp. Devel.260.09kN/A53
Mr. William C. RobertsVP of Investor Relations & Corp. CommunicationsN/AN/A48
Ms. Suzanne M. HanlonVP of HR, Gen. Counsel and Sec.N/AN/A60
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Corporate Governance

Zynerba Pharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.